In a landmark decision, a $56 million class action settlement has been reached with multiple pharmaceutical companies involved in the manufacturing and marketing of certain Alzheimer's disease medications. The lawsuit claimed that companies, including Actavis, Merz, Teva, Dr. Reddy's, and Wockhardt, conspired to keep generic versions